KALV vs ANL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
KALV Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to KalVista Pharmaceuticals, Inc. Common Stock (KALV) driven by superior Valuation, Growth & Margin, Options & Structure while ANL counters with relative strength in Momentum & Technical. Fundamentally, KALV trades at 25.4x Forward P/E with -57.4% operating margin (+30.7% YoY revenue) versus ANL at N/M Forward P/E and -123.5% operating margin (+178.1% YoY). In options structure, KALV sits in UNCLASSIFIED (31st %ile IV; Dealer Gamma Walls on Pro) against ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | KALV | ANL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.4B | $677.5M | Larger Scale | KALV |
| Trailing P/E Ratio Valuation | 25.4x | N/M | Lower Multiple | KALV |
| Forward P/E Ratio Valuation | 25.4x | N/M | Lower Multiple | KALV |
| Revenue Growth (YoY) Growth | +30.7% | +178.1% | Higher Growth | ANL |
| Operating Margin (TTM) Profitability | -57.4% | -123.5% | Higher Margin | KALV |
| Net Profit Margin Profitability | -118.7% | -124.8% | Higher Margin | KALV |
| Return on Equity (ROE) Capital Efficiency | -190.2% | -20.2% | Higher ROE | ANL |
| 52-Week Range Position Momentum | 100% ($10โ$27) | 56% ($1โ$17) | Stronger Trend | KALV |
| Beta / 30D Volatility Risk Regime | 0.85ฮฒ ยท 2% Vol | 2.61ฮฒ ยท 79% Vol | Lower Realized Risk | KALV |
| Unified Institutional Score Composite Signal | 55.1 / 100 (HOLD) | 48.3 / 100 (HOLD) | Higher Composite | KALV |